A real-life analysis of patients with rheumatologic\rdiseases on biological treatments: Data from TURKBIO\rRegistry

Simple item page
dc.contributor.authorgercek can
dc.contributor.authorFatos Onen
dc.contributor.authorDilek Solmaz
dc.contributor.authorYAVUZ PEHLIVAN
dc.contributor.authorCemal Bes
dc.contributor.authorSema Yilmaz
dc.contributor.authorMerih Birlik
dc.contributor.authorSedat Çapar
dc.contributor.authorSONER ŞENEL
dc.contributor.authorSuleyman Serdar Koca
dc.contributor.authormehmet akif öztürk
dc.contributor.authorÖzgül Soysal Gündüz
dc.contributor.authorAyse Cefle
dc.contributor.authorServet Akar
dc.contributor.authorIsmail Sari
dc.contributor.authorAyten Yazici
dc.contributor.authorABDURRAHMAN TUFAN
dc.contributor.authorSEMINUR HAZNEDAROGLU
dc.contributor.authorGozde Yildirim-Cetin
dc.contributor.authorServet Yolbas
dc.contributor.authorBerna Goker
dc.contributor.authorEdiz Dalkılıç
dc.contributor.authorNurullah Akkoç
dc.contributor.authorŞükran Erten
dc.contributor.authorNevsun Inanc
dc.contributor.authorHaner Direskeneli
dc.contributor.authorNiels Steen Krogh
dc.contributor.authorSule Yavuz
dc.contributor.authorFatih Yıldız
dc.contributor.authorNeslihan Yilmaz
dc.date.accessioned2025-04-14T05:52:28Z
dc.date.available2025-04-14T05:52:28Z
dc.date.issued2022
dc.description.abstractObjective: TURKBIO registry, established in 2011, is the first nationwide biological database in Turkey.\rThis study aimed to provide an overview of TURKBIO data collected by June 2018.\rMethods: The registry included adult patients with rheumatoid arthritis (RA), ankylosing spondylitis\r(AS), nonradiographic axial spondyloarthritis (nr-AxSpA), and psoriatic arthritis (PsA). Demographic and\rclinical features, disease activity markers, and other follow-up parameters, current and previous treatments,\rand adverse events were registered electronically at each visit using open-source software. The\rregistration of patient-reported outcome measures was carried out electronically by the patients using\rtouch screens.\rResults: TURKBIO registry included a total of 41,145 treatment series with biologicals. There were 2,588\rpatients with axSpA (2,459 AS and 129 nr-axSpA), 2,036 with RA, and 428 with PsA. The total number\rof patients, including those with other diagnoses, was 5,718. In the follow-up period, the number of\rpatients and also visits steadily increased by years. The yearly mean number of visits per patient was\rfound to be 2.3. Significant improvements in disease activity and health assessment parameters were\robserved following the biological treatments. Biologics were often given in combination with a conventional\rsynthetic disease-modifying antirheumatic drug in patients with RA. Infections were the\rmost commonly seen adverse events, followed by allergic reactions. Tuberculosis was observed in 12\rpatients, malignancy in 18, and treatment-related mortality in 31.\rConclusion: TURKBIO provided a valuable real-life experience with the use of biologics in rheumatic\rdiseases in Turkey.
dc.identifier.DOI-ID10.5152/eurjrheum.2022.21060
dc.identifier.urihttp://hdl.handle.net/20.500.14701/55360
dc.language.isoİngilizce
dc.subjectGenel ve Dahili Tıp
dc.titleA real-life analysis of patients with rheumatologic\rdiseases on biological treatments: Data from TURKBIO\rRegistry

Files

Collections

TR-Dizin Koleksiyonu